Liquid biopsy epigenomic profiling for cancer subtyping.
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
15
07
2023
accepted:
21
09
2023
medline:
27
11
2023
pubmed:
22
10
2023
entrez:
21
10
2023
Statut:
ppublish
Résumé
Although circulating tumor DNA (ctDNA) assays are increasingly used to inform clinical decisions in cancer care, they have limited ability to identify the transcriptional programs that govern cancer phenotypes and their dynamic changes during the course of disease. To address these limitations, we developed a method for comprehensive epigenomic profiling of cancer from 1 ml of patient plasma. Using an immunoprecipitation-based approach targeting histone modifications and DNA methylation, we measured 1,268 epigenomic profiles in plasma from 433 individuals with one of 15 cancers. Our assay provided a robust proxy for transcriptional activity, allowing us to infer the expression levels of diagnostic markers and drug targets, measure the activity of therapeutically targetable transcription factors and detect epigenetic mechanisms of resistance. This proof-of-concept study in advanced cancers shows how plasma epigenomic profiling has the potential to unlock clinically actionable information that is currently accessible only via direct tissue sampling.
Identifiants
pubmed: 37865722
doi: 10.1038/s41591-023-02605-z
pii: 10.1038/s41591-023-02605-z
pmc: PMC10695830
doi:
Substances chimiques
Biomarkers, Tumor
0
Circulating Tumor DNA
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2737-2741Subventions
Organisme : NCI NIH HHS
ID : P01 CA228696
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA137008
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA156732
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA156734
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.
Références
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Nature. 2020 Aug;584(7820):244-251
pubmed: 32728217
Nat Biotechnol. 2021 May;39(5):586-598
pubmed: 33432199
Nature. 2023 Jan;613(7943):355-364
pubmed: 36599988
Clin Cancer Res. 2022 Mar 01;28(5):928-938
pubmed: 34907080
Nat Commun. 2021 Mar 30;12(1):1979
pubmed: 33785741
Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21931-6
pubmed: 21106759
Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-14
pubmed: 35580290
Nat Commun. 2017 Nov 6;8(1):1324
pubmed: 29109393
BMC Med Genomics. 2020 Jul 3;13(1):92
pubmed: 32620123
Bioinformatics. 2013 Jan 15;29(2):266-7
pubmed: 23162058
Nature. 2019 Jun;570(7761):385-389
pubmed: 31142840
Nat Commun. 2021 Oct 1;12(1):5775
pubmed: 34599169
Nat Commun. 2022 Dec 3;13(1):7475
pubmed: 36463275
Nat Genet. 2020 Aug;52(8):790-799
pubmed: 32690948
Cell. 2016 Jan 14;164(1-2):57-68
pubmed: 26771485
Bioinformatics. 2015 Jul 15;31(14):2382-3
pubmed: 25765347
Cell. 2017 Feb 9;168(4):629-643
pubmed: 28187285
Science. 2018 Oct 26;362(6413):
pubmed: 30361341
Nat Med. 2013 Nov;19(11):1438-49
pubmed: 24202396
Nucleic Acids Res. 2019 Jan 8;47(D1):D729-D735
pubmed: 30462313
Lung Cancer. 2020 Sep;147:244-251
pubmed: 32759018
Cancer Discov. 2023 Mar 1;13(3):632-653
pubmed: 36399432
Nat Med. 2020 Jul;26(7):1041-1043
pubmed: 32572266
Bioinformatics. 2010 Mar 15;26(6):841-2
pubmed: 20110278
Cell. 2018 Jul 12;174(2):422-432.e13
pubmed: 29909987
Nat Methods. 2018 Feb;15(2):123-126
pubmed: 29309061